Results 21 to 30 of about 1,211,683 (168)

Computational Approaches for Predicting Drug-Disease Associations: A Comprehensive Review [PDF]

arXiv, 2023
In recent decades, traditional drug research and development have been facing challenges such as high cost, long timelines, and high risks. To address these issues, many computational approaches have been suggested for predicting the relationship between drugs and diseases through drug repositioning, aiming to reduce the cost, development cycle, and ...
arxiv  

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan

Frontiers in Pharmacology, 2021
In Japan, medical costs are increasing annually, and the increase in national medical costs, particularly in the direct cost of managing adverse drug events, is high. An in-depth understanding of these costs is important for their reduction.
Hayato Katsuno, Hayato Katsuno, Tomoya Tachi, Tomoya Tachi, Takuya Matsuyama, Mayuko Sugioka, Satoshi Aoyama, Tomohiro Osawa, Yoshihiro Noguchi, Masahiro Yasuda, Chitoshi Goto, Takashi Mizui, Hitomi Teramachi, Hitomi Teramachi   +13 more
doaj   +1 more source

Consórcio de medicamentos no Paraná: análise de cobertura e custos A drug consortium in Paraná: analysis of coverage and costs

Revista de Administração Pública, 2007
A redução de custos na compra de medicamentos é preocupação constante dos administradores públicos. Este artigo analisa a cobertura e custos do Consórcio Paraná Saúde (CPS), constituído para aquisição de medicamentos para prefeituras do Paraná.
Alide Marina Biehl Ferraes, Luiz Cordoni Junior   +1 more
doaj   +1 more source

How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements

MDM Policy & Practice, 2021
Background. Pharmaceutical risk sharing agreements (RSAs) are commonly used to manage uncertainties in costs and/or clinical benefits when new drugs are added to a formulary.
Gregory S. Zaric
doaj   +1 more source

Therapeutic Drug Monitoring by Pharmacists: Does It Reduce Costs? [PDF]

Global Journal on Quality and Safety in Healthcare, 2020
Therapeutic drug monitoring (TDM) has as its main objective to ensure that the plasma drug concentration remains within the appropriate range. Regarding the economic dimension of TDM, it is known that there are gains in health outcomes; however, there is
Pedro Cardoso, C. Santos, Francisco Rocha-Gonçalves   +2 more
doaj   +1 more source

Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules [PDF]

arXiv, 2021
Evaluating the blood-brain barrier (BBB) permeability of drug molecules is a critical step in brain drug development. Traditional methods for the evaluation require complicated in vitro or in vivo testing. Alternatively, in silico predictions based on machine learning have proved to be a cost-efficient way to complement the in vitro and in vivo methods.
arxiv  

Referral Burden and Cost of Outpatient Care of Patients Covered by the Rural Insurance Fund before and after the Implementation of Electronic Referral System in Golestan Province

Rāhburdhā-yi Mudīriyyat dar Niẓām-i Salāmat, 2021
Background: Part of the major health costs is related to outpatient care. Since the costs of diagnosis and treatment are increasing rapidly and increasingly, this study was conducted to determine the referral burden and cost of outpatient care of ...
Anis Abbasi, Mohammad Javad Kabir, Fatemeh Kavian Telouri, Alireza Heidari, Zahra Khatirnamani, Narges Rafiei, Anahita Keshavarzi   +6 more
doaj  

Volumetric Dimensioning of Strategic Stock; SOP, a step further toward a better flow control [PDF]

arXiv, 2021
This paper is presenting a real case study. It focuses on a drug stock management problem within a Tunisian monopoly in drugs distribution, PCT. The commercial service aims to optimize the drug stock management and procurement while reducing drug shortage and cost of stock management and to have a clear vision on the estimation of the strategic stock ...
arxiv  

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Current Oncology
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation.
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist   +14 more
doaj   +1 more source

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Cancer Medicine, 2019
Background The cost of new anticancer drugs is rising. We aimed to assess the clinical benefit and price of anti‐cancer drugs approved by the US Food and Drug Administration (FDA) for advanced gastrointestinal cancers. Methods Drugs approved between 2006
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova   +8 more
doaj   +1 more source